Dendreon Corp (DNDNQ) 0.0359 $DNDNQ Dendritic Cell and

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Dendreon Corp (DNDNQ) 0.0359 $DNDNQ

Dendritic Cell and CAR-T Therapies Market, 2014 - 2024
PR Newswire - Wed May 13, 1:01PM CDT
INTRODUCTIONCancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body's own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). These antibody based drugs are passive immunotherapeutics. There has been a surge of interest in other classes of active immunotherapeuticsincludingcell based therapies such as Dendritic Cell Therapy (DCT) and Chimeric Antigen Receptor T cell Therapy (CAR-T).

After Failure Of Phase 3 Trial, Aerie Pharmaceuticals Struggles To Find Value
Edward Vranic, CFA - at Seeking Alpha - Tue Apr 28, 7:46AM CDT

EYES: 12.46 (-0.25), AERI: 11.26 (+0.01)

Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.68 (-0.01), NBS: 2.38 (+0.07), OSIR: 17.29 (-0.18), BCLI: 3.66 (-0.04), MDVN: 122.90 (-0.47), INO: 7.97 (-0.02), CYTX: 0.66 (-0.02), STEM: 0.62 (+0.01), JUNO: 43.37 (-1.52), ATHX: 1.27 (-0.01), CUR: 1.70 (-0.04), BLUE: 154.42 (-2.98), VRTX: 126.21 (+3.21), AMGN: 162.36 (+0.38), KERX: 10.33 (+0.11), OMER: 20.88 (-0.01), KITE: 50.02 (-2.24), GILD: 109.30 (+0.56), MRK: 60.23 (+0.45), TEVA: 60.23 (-0.99)

Cancer Targeted Therapy Market & Clinical Insight 2015
M2 - Thu Apr 09, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq2wq/cancer_targeted) has announced the addition of the "Cancer Targeted Therapy Market & Clinical Insight 2015" report to their offering. Cancer targeted therapeutics global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug design development, manufacturing and marketing. However, they have limited targeting efficacy and limited products could be used for multiple cancer indications. This scenario gave way to market introduction of large molecule cancer targeted therapeutics having better pharmacological profiles. Clinical Insight on Cancer Targeted Therapies Pipeline Covered in Report: - Cancer Targeted Tyrosine Kinase Inhibitors Pipeline: 388 TKI - Cancer Targeted Angiogenesis Inhibitors Pipeline: 166 Angiogenesis Inhibitors - Cancer Vaccines Pipeline: 289 Cancer Vaccines - Cancer Targeted Monoclonal Antibodies: 605 mAb - Oncogene Inhibitors Pipeline: 185 oncogene inhibitors Cancer Targeted Therapy Market & Clinical Insight Report Highlight: - Introduction & Categorization of Cancer Targeted Therapies - Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies - Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase - Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline - Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies - Global Cancer Targeted Therapeutics Market Dynamics - Future Prospects of Cancer Targeted Therapies Key Topics Covered: 1. Introduction to Cancer Targeted Therapeutics 2. Need for Cancer Targeted Therapeutics 3. Categorization of Cancer Targeted Therapies 4. Consideration of Cancer Vaccines as Targeted Therapeutics 5. Mechanism of Cancer Vaccines 6. Mechanisms of Cancer Targeted Monoclonal Antibodies 7. Mechanism of Cancer Targeted Tyrosine Kinase Therapeutics 8. Mechanism of Oncogene Inhibitors 9. Global Cancer Targeted Therapy Market Overview 10. Global Cancer Targeted Therapeutics Market Dynamics 11. Future Prospects of Cancer Targeted Therapeutics 12. Cancer Targeted Monoclonal Antibodies Pipeline by Company, Indication & Phase 13. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country 14. Global Cancer Vaccines Clinical Pipeline Insight by Company, Indication & Phase 15. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 16. Oncogene Inhibitors Pipeline by Company, Indication & Phase 17. Marketed Oncogene Inhibitors by Company & Indication 18. Cancer Targeted Tyrosine Kinase Clinical Trial by Company, Indication & Phase 19. Marketed Cancer Targeted Tyrosine Kinase Inhibitors 20. Cancer Targeted Angiogenesis Inhibitors Therapy Pipeline by Company, Phase & Indication 21. Marketed Cancer Targeted Angiogenesis Inhibitors 22. Competitive Landscape - Advaxis - Bind Therapeutics - Boehringer Ingelheim - Bristol Mayer Squibb - Celldex Therapeutics - Dendreon Corporation - Eli Lily - GalaxoSmithKline - Galena Biopharma - Genetech - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Johnson & Johnson - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Merck - Novartis - Peregrine Pharmaceuticals - Pfizer - Roche - Sanofi - Seattle Genetics - Teva For more information visit http://www.researchandmarkets.com/research/4l...r_targeted
JNJ: 102.30 (+0.47), INO: 7.97 (-0.02), NWBO: 8.12 (+0.07), MRK: 60.23 (+0.45), CLDX: 25.81 (+0.06), NLNK: 39.69 (+1.57), GALE: 1.35 (-0.01), IMUC: 0.48 (+0.01), NVS: 103.75 (-0.15)

Should Investors Toss in the Towel on Amarin Corp Plc?
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Thu Mar 26, 11:02AM CDT
Investing in biotech is a risky business, and investing in emerging clinical stage companies doubly so. Many investors have jumped on the enticing bandwagon of the next blockbuster drug, only to have their hopes dashed before the promise is...
PFE: 33.99 (+0.05), AMRN: 1.93 (+0.03)

Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 33.36 (+0.12), CASM: 1.26 (unch), AMRN: 1.93 (+0.03), XON: 40.08 (-0.90), OSIR: 17.29 (-0.18), CPIX: 6.69 (-0.01), AMED: 28.49 (-0.04), CTIC: 1.80 (+0.04), INSY: 59.00 (+0.17), ECYT: 6.02 (unch), CMRX: 40.15 (+0.31), KYTH: 46.55 (-0.10), TRIB: 16.37 (-0.27), GALE: 1.35 (-0.01), ARNA: 4.25 (unch), XLRN: 31.84 (-0.02), ACRX: 3.16 (-0.09), ENDP: 85.35 (+0.33), DPLO: 35.06 (+0.36), SLXP: 172.96 (+0.15), PPHM: 1.37 (+0.05), MYL: 70.67 (-0.86), CBPO: 101.56 (+0.67), RGEN: 41.63 (+0.26), HALO: 16.42 (+0.11), ALIM: 4.49 (-0.06), ACHN: 9.57 (+0.05), GERN: 3.89 (-0.02), DARA: 0.68 (-0.06), SCMP: 15.94 (-0.01), ICPT: 306.23 (-0.84), CDXS: 4.50 (-0.13), PCRX: 77.83 (+0.95), PBYI: 177.01 (+6.34), FOLD: 10.53 (+0.03)

Valeant Pharmaceuticals Buys Salix Pharmaceuticals in $14.5 Billion Megadeal
at The Street - Mon Feb 23, 11:03AM CST
Following last year's failed attempt to purchase Allergan, the Canadian pharmaceutical giant continues its acquisition strategy with its latest deal.
AGN: 240.22 (+2.88), VRX: 224.63 (+1.81), ACT: 296.60 (-0.86), SHPG: 254.45 (+3.99), PFE: 33.99 (+0.05), AZN: 69.29 (-0.81), SLXP: 172.96 (+0.15), ABBV: 65.99 (+0.02), HSP: 88.10 (-0.08)

Report: Valeant to buy Salix for $10.1B
Seeking Alpha - at Seeking Alpha - Sun Feb 22, 5:53AM CST

ENDP: 85.35 (+0.33), VRX: 224.63 (+1.81), SHPG: 254.45 (+3.99), SLXP: 172.96 (+0.15)

Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 224.63 (+1.81), ACT: 296.60 (-0.86), MDT: 76.42 (+0.16), XON: 40.08 (-0.90), CTIC: 1.80 (+0.04), PFNX: 13.70 (+0.60), JNJ: 102.30 (+0.47), ANTM: 161.37 (+1.37), NVAX: 8.54 (-0.09), SHPG: 254.45 (+3.99), ABBV: 65.99 (+0.02), TBPH: 14.69 (-0.24), SNY: 50.52 (-0.27), ALQA: 4.48 (-0.27), REGN: 489.01 (-2.42), ONCY: 0.71 (unch), PFE: 33.99 (+0.05), SLXP: 172.96 (+0.15), EPRS: 5.61 (-0.14), AMGN: 162.36 (+0.38), NKTR: 11.13 (+0.20), ZTS: 46.49 (+0.21), GILD: 109.30 (+0.56), ACHN: 9.57 (+0.05), GERN: 3.89 (-0.02)

Wall Street Breakfast: Apple's Market Cap Closes Above $700B
Wall Street Breakfast - at Seeking Alpha - Wed Feb 11, 5:30AM CST

TSLA: 248.84 (+4.74), VRX: 224.63 (+1.81), AMX: 21.00 (+0.22), HAL: 46.70 (+0.26), PBR: 10.13 (+0.20), ANTM: 161.37 (+1.37), FSLR: 56.72 (+0.16), SPY: 212.44 (+0.23), QQQ: 109.58 (unch), ARMH: 51.80 (-0.80), MSFT: 48.29 (-0.43), AAPL: 128.77 (-0.18), INTU: 102.33 (-1.49)

Reuters: Valeant close to Dendreon purchase
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 1:49AM CST

VRX: 224.63 (+1.81)

Dendreon Announces Expiration of Bid Deadline in Connection with Agreement to Sell Substantially All Assets to Valeant
Business Wire - Tue Feb 10, 4:15PM CST
--Dendreon and Valeant to Seek Court Approval of Sale on February 20, 2015
VRX: 224.63 (+1.81), VRX.TO: 270.02 (+2.67)

Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)
PR Newswire - Thu Feb 05, 9:30AM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that yesterday it entered into an amended and restated "stalking horse" asset purchase agreement to acquire the world-wide rights to Dendreon's PROVENGE® (sipuleucel-T) product and certain other assets of Dendreon Corporation ("Dendreon" . In response to competing bids, Valeant has raised its offer to $400 million in cash for the assets, which realized combined revenues of approximately $300 million in 2014.
VRX: 224.63 (+1.81), VRX.TO: 270.02 (+2.67)

Is Valeant Making A Mistake By Purchasing Rights To Provenge?
Investing Healthcare - at Seeking Alpha - Tue Feb 03, 5:22PM CST

VRX: 224.63 (+1.81)

Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST

BCRX: 10.75 (+0.20), ACT: 296.60 (-0.86), VRX: 224.63 (+1.81), PCYC: 255.42 (-0.50), ZSPH: 49.05 (+0.07), RMTI: 10.03 (-0.25), BCLI: 3.66 (-0.04), SIEN: 19.84 (-0.77), JNJ: 102.30 (+0.47), ECYT: 6.02 (unch), SNY: 50.52 (-0.27), LENS: 8.79 (-0.21), REGN: 489.01 (-2.42), SYK: 95.51 (+0.25), PFE: 33.99 (+0.05), SLXP: 172.96 (+0.15), AMGN: 162.36 (+0.38), APPY: 0.53 (+0.01), MNKD: 3.99 (+0.36), CELG: 115.53 (+0.45), ISRG: 503.66 (+1.31), GILD: 109.30 (+0.56), ANIP: 52.12 (+0.55), MRK: 60.23 (+0.45), ALXN: 160.56 (-1.13), CCXI: 7.21 (-0.09), ICPT: 306.23 (-0.84), AEZS: 0.43 (-0.01), ATRS: 2.08 (-0.09), NASH: 32.06 (+0.33)

Regeneron Shows Biotech Investors Have Left Their Wildcatting Days
Dana Blankenhorn - at Seeking Alpha - Fri Jan 30, 11:12AM CST

BIIB: 391.24 (-3.11), PFE: 33.99 (+0.05), MRK: 60.23 (+0.45), XOM: 87.35 (+0.38), AMGN: 162.36 (+0.38), REGN: 489.01 (-2.42), SLB: 92.14 (-0.03), CELG: 115.53 (+0.45)

Wall Street Breakfast: Amazon Shares Surge After Profit Beat
Wall Street Breakfast - at Seeking Alpha - Fri Jan 30, 5:31AM CST

AMZN: 426.00 (-6.28), VRX: 224.63 (+1.81), SHAK: 69.39 (+3.89), OSTK: 22.37 (+0.66), CCRN: 10.71 (-0.03), LPG: 13.57 (+0.05), GOOG: 533.85 (-4.55), CVC: 20.43 (+0.13), PBR: 10.13 (+0.20), V: 69.57 (-0.43), SPY: 212.44 (+0.23), QQQ: 109.58 (unch), TRP: 45.39 (+0.69), XCO: 1.69 (unch), GOOGL: 546.49 (-2.71), HMC: 35.00 (-0.08), VZ: 49.79 (-0.18)

Dendreon's Asset Rummage Sale Completes the Circle of Life
at The Street - Fri Jan 30, 5:01AM CST
Valeant Pharmaceuticals is in a tentative deal to acquire the assets of Dendreon -- mostly its prostate-cancer vaccine Provenge and manufacturing facilities -- for $296 million in cash.
VRX: 224.63 (+1.81), JUNO: 43.37 (-1.52)

Valeant to purchase Dendreon's Provenge
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 2:47AM CST

VRX: 224.63 (+1.81)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hyster-Yale's $125 Million Convertible Debt Shuffle

Updated Category News Views 86

Forklifts do not make headlines often, but debt terms sure can. Hyster-Yale has proposed a $125 million private offering of convertible senior notes due November 15, 2031, with buyers able to take another $18.75 million if the initial purchasers exercise their option. For NYSE:HY holders, this is not a victory lap or a distress flare by itself. It is a refinancing...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 152

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 91

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 89

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 18

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 61

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
OCEG Faces China's Demographic Test After 40 Years

Updated Category News Views 44

A school group that once opened 35 kindergartens in a year is admitting the old playbook has run its course. That is the real message behind Oriental Cambridge Education Group's 40th-anniversary talk, not the balloons and ceremonial language. OCEG operates more than 170 institutions across 39 Chinese cities, and its chairman, Yu Yue, says the next chapter will be judged...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 162

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 64

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 87

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading

Top 5 Most Recently Viewed Articles

Uptown Cheapskate and Kid to Kid Shaping the Resale Future

Updated Category News Views 413

Innovating the Resale Landscape with Uptown Cheapskate and Kid to Kid BaseCamp Franchising is witnessing a remarkable transformation in the retail sector through its brands, Uptown Cheapskate and Kid to Kid. With over 260 stores across various U.S. states and additional international locations, these brands are redefining thrift shopping by merging the thrill of the hunt...

Continue Reading
Midea's Indoor Hybrid Heat Pump Revolutionizes Home Heating

Updated Category News Views 348

Midea’s Innovative CirQHP Indoor Hybrid Heat Pump Midea, a well-known leader in the HVAC industry, has unveiled its latest creation: the CirQHP Indoor Hybrid heat pump. This cutting-edge system has been honored with the Innovative Heating Technology Gold Award at an international exhibition. The CirQHP Indoor Hybrid allows homeowners to enjoy a modern heating solution...

Continue Reading
Exploring NYC's Future Guaranteed Income Program for Residents

Updated Category News Views 168

New York City’s Guaranteed Income Initiative New York City is embarking on a transformative journey to introduce a guaranteed income program aimed at helping those in need. Planned for 2026, this program will distribute $15,800 annually to residents who are facing economic hardships. It's an innovative approach to addressing poverty and housing insecurity within the...

Continue Reading
Investigating Potential Shareholder Dilemmas for TXNM, STRR, PVBC

Updated Category News Views 145

Understanding Shareholder Rights and Legal Investigations In the evolving landscape of corporate mergers and acquisitions, shareholder rights play a crucial role. Many companies are involved in significant transactions that raise questions for their shareholders. Today, we explore multiple companies undergoing scrutiny due to potential violations related to shareholder...

Continue Reading
Legal Battle Unfolds as U.S. Steel and Nippon Steel Challenge Biden

Updated Category News Views 215

U.S. Steel and Nippon Steel Challenge Government Actions United States Steel Corp (NYSE: X) and Nippon Steel Corp have taken significant legal steps against the Biden administration after the President's decision to block their ambitious $14.9 billion merger. This action by the government has raised questions about the motivations behind the blockade. The Legal Actions...

Continue Reading